skip to main content

H.R. 2375: Preserve Access to Affordable Generics and Biosimilars Act

Call or Write Congress

To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.

The bill’s titles are written by its sponsor.

Sponsor and status

Jerrold Nadler

Sponsor. Representative for New York's 10th congressional district. Democrat.

Read Text »
Last Updated: Apr 29, 2019
Length: 20 pages
Apr 29, 2019
116th Congress (2019–2021)

Ordered Reported on Apr 30, 2019

The committees assigned to this bill sent it to the House or Senate as a whole for consideration on April 30, 2019.

3% chance of being enacted according to Skopos Labs (details)

Position statements

What legislators are saying

House Judiciary Unanimously Passes Bipartisan Bills to Lower Prescription Drug Prices
    — Rep. Jerrold Nadler [D-NY10] (Sponsor) on Apr 30, 2019

Congressman Cohen Works to Lower Prescription Drug Costs
    — Rep. Steve Cohen [D-TN9] (Co-sponsor) on Apr 30, 2019

Chairman Nadler Statement for the Markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act
    — Rep. Jerrold Nadler [D-NY10] (Sponsor) on Apr 30, 2019

More statements at ProPublica Represent...

What stakeholders are saying

R Street Institute estimates H.R. 2375 will save $544 million through 2029.


Apr 29, 2019

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Apr 30, 2019
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

If this bill has further action, the following steps may occur next:
Passed House

Passed Senate

Signed by the President

H.R. 2375 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Bills numbers restart every two years. That means there are other bills with the number H.R. 2375. This is the one from the 116th Congress.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 2375 — 116th Congress: Preserve Access to Affordable Generics and Biosimilars Act.” 2019. December 1, 2020 <>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from, the official portal of the United States Congress. is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.